Zhejiang Hisun Study Demonstrates HS016 Biosimilar to AbbVie’s Humira® (Adalimumab) is Efficacious and Safe in IBD Patients

A Zhejiang Hisun Pharmaceuticals sponsored study published in Frontiers in Pharmacology has found that HS016, biosimilar to AbbVie’s Humira® (adalimumab) was safe and effective in Chinese inflammatory bowel disease (IBD) patients.

Hisun completed its stage III clinical trials of HS016 back in early 2020.